Market closedNon-fractional
IDEAYA Biosciences/IDYA
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About IDEAYA Biosciences
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
Ticker
IDYA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
124
Website
www.ideayabio.com
IDYA Metrics
BasicAdvanced
$2.6B
Market cap
-
P/E ratio
-$2.01
EPS
0.78
Beta
-
Dividend rate
Price and volume
Market cap
$2.6B
Beta
0.78
Financial strength
Current ratio
28.42
Quick ratio
27.996
Long term debt to equity
0.134
Total debt to equity
0.257
Management effectiveness
Return on assets (TTM)
-15.00%
Return on equity (TTM)
-20.31%
Valuation
Price to revenue (TTM)
139.63
Price to book
2.68
Price to tangible book (TTM)
2.68
Price to free cash flow (TTM)
-16.06
Growth
Revenue change (TTM)
-67.32%
Earnings per share change (TTM)
28.67%
3-year revenue growth
-16.66%
3-year earnings per share growth
20.75%
What the Analysts think about IDYA
Analyst Ratings
Majority rating from 11 analysts.
IDYA Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$40M
16.52%
Profit margin
0.00%
-100.00%
IDYA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.50
-$0.46
-$0.52
-$0.53
-
Expected
-$0.56
-$0.49
-$0.47
-$0.51
-$0.54
Surprise
-10.16%
-7.00%
11.23%
2.99%
-
IDYA News
AllArticlesVideos
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PRNewsWire·6 days ago
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer
PRNewsWire·1 week ago
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
PRNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for IDEAYA Biosciences stock?
IDEAYA Biosciences (IDYA) has a market cap of $2.6B as of July 04, 2024.
What is the P/E ratio for IDEAYA Biosciences stock?
The price to earnings (P/E) ratio for IDEAYA Biosciences (IDYA) stock is 0 as of July 04, 2024.
Does IDEAYA Biosciences stock pay dividends?
No, IDEAYA Biosciences (IDYA) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next IDEAYA Biosciences dividend payment date?
IDEAYA Biosciences (IDYA) stock does not pay dividends to its shareholders.
What is the beta indicator for IDEAYA Biosciences?
IDEAYA Biosciences (IDYA) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell IDEAYA Biosciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.